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We show here that the neurotrophin nerve growth
factor (NGF), which has been shown to be a mitogen for
breast cancer cells, also stimulates cell survival through
a distinct signaling pathway. Breast cancer cell lines
(MCF-7, T47-D, BT-20, and MDA-MB-231) were found to
express both types of NGF receptors: p140trkA and
p75NTR. The two other tyrosine kinase receptors for neu-
rotrophins, TrkB and TrkC, were not expressed. The
mitogenic effect of NGF on breast cancer cells required
the tyrosine kinase activity of p140trkA as well as the
mitogen-activated protein kinase (MAPK) cascade, but
was independent of p75NTR. In contrast, the anti-apo-
ptotic effect of NGF (studied using the ceramide ana-
logue C2) required p75NTR as well as the activation of
the transcription factor NF-kB, but neither p140trkA nor
MAPK was necessary. Other neurotrophins (BDNF,
NT-3, NT-4/5) also induced cell survival, although not
proliferation, emphasizing the importance of p75NTR in
NGF-mediated survival. Both the pharmacological
NF-kB inhibitor SN50, and cell transfection with IkBm,
resulted in a diminution of NGF anti-apoptotic effect.
These data show that two distinct signaling pathways
are required for NGF activity and confirm the roles
played by p75NTR and NF-kB in the activation of the
survival pathway in breast cancer cells.
Nerve growth factor (NGF)1 is the archetypal member of the
neurotrophin superfamily, which also includes brain-derived
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5,
and NT-6 (1). NGF interacts with two classes of membrane
receptor: the TrkA proto-oncogene product p140trkA, which pos-
sesses intrinsic tyrosine kinase activity, and a secondary re-
ceptor, p75NTR, that belongs to the tumor necrosis factor (TNF)
receptor family (2). The stimulation of cell survival and cell
differentiation by NGF and other neurotrophins have been
described primarily in neuronal cell systems (3). Although the
neurotrophic effect through p140trkA is known to involve the
MAPK cascade, the role of p75NTR is still controversial; there is
evidence that it can both positively and negatively regulate
neuronal cell death and differentiation, depending on the cell
type examined (4). In some cases, p75NTR is an inducer of
apoptosis, even without NGF stimulation (5), whereas in other
cases the activation of p75NTR by NGF results in a protection
from cell death (6). In addition to its neurotrophic function,
other activities of NGF have been described. For example, NGF
can modulate gene expression in monocytes (7), it is chemotac-
tic for melanocytes (8), and its inhibition on p75NTR can block
the migration of Schwann cells (9). NGF also stimulates the
proliferation of chromaffin cells (10), lymphocytes (11), and
keratinocytes (12). We have previously shown that NGF is
mitogenic for cancerous but not normal human breast cells
(13), and these data, as well as others showing a role for NGF
in the stimulation of prostatic cancer cells (14–17), implicate
NGF in non-neuronal carcinogenesis.
Both cellular proliferation as well as tumor cell survival
are crucial for malignant progression. The effect of NGF on
the survival of cancer cells through the p75NTR receptor has
been shown for neuroblastoma (18) and schwannoma (6). In
prostate cancer, p75NTR has been shown to be a mediator of
NGF’s effects during critical phases of developmental cell
death and carcinogenic progression (19). To date only the
mitogenic effect of NGF for breast cancer cells has been
described (13), with its roles in the control of breast cancer
cell survival unknown.
In this study, we have shown that, in addition to its mito-
genic effect, NGF is also an anti-apoptotic factor for breast
cancer cells. These cells express mRNA for both p140trkA and
p75NTR receptors. Our results indicate that the mitogenic effect
of NGF requires p140trkA and the MAPK cascade, but not the
p75NTR receptor, whereas the promotion of cell survival strictly
requires p75NTR as well as NF-kB, but not p140trkA and MAPK.
Thus the mitogenic and anti-apoptotic effects of NGF on breast
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cancer cells are mediated through two different signaling
pathways.
EXPERIMENTAL PROCEDURES
Materials—Cell culture reagents were purchased from BioWhittaker
(France) except insulin, which was obtained from Organon (France).
Recombinant human nerve growth factor, brain derived growth factor
(BDNF), and neurotrophins 3 (NT-3) and 4 (NT-4) were from R & D
Systems (UK). K-252a (inhibitor of trk-tyrosine kinase activity) and
PD98059 (inhibitor of MAPK cascade) were from Calbiochem (France).
The mouse monoclonal anti-NGF receptor (p75NTR) antibody was from
Euromedex (France) and was previously described for its ability to block
the interaction between p75NTR and NGF (20). The anti-lamin B (C-20),
goat polyclonal IgG, and the polyclonal anti-p140trkA (trk763) were from
Santa Cruz Biotechnology. C2 ceramide analogue (N-acetyl-D-sphingo-
sine), Hoechst 33258, and electrophoresis reagents were from Sigma
Chemical Co. (France). The SN50 NF-kB inhibitor peptide, the rabbit
polyclonal anti-NF-kB p65 antibody, was obtained from TEBU (France).
Anti-PARP antibody was from Oncogene Research Products (UK).
Primers and probes for TrkA and p75NTR, probe for TATA box binding
protein (TBP) were from Eurogentec (Belgium). RT-PCR reagents were
from Applied Biosystems (France). Lipofectin reagent and Opti-MEM
were provided by Life Technologies, Inc. (France). The green fluores-
cence protein plasmid (EGFPC1) was purchased from CLONTECH, and
the dominant-negative IkBa mutant (IkBm) expression vectors (in
PCDNA3) containing a Ser to Ala substitution at residues 32 and 36
were obtained from Dr. Jean Feuillard (UPRES EA 1625, Bobigny,
France). p65 (rel-A) and c-rel cDNA were cloned at EcoRI site in PSVK3
expression plasmid. All vectors were obtained from Dr. Pascale
Cre´pieux (McGill University, Montreal). The SY5Y subclone of SK-
N-SH neuroblastoma cell line was a kind gift of Dr. Luc Bue´e (INSERM,
U422, Lille, France). NT-2 (Ntera/D1) human neural precursor cells
(Stratagene) are derived from a clone of the NT-2 teratocarcinoma.
Cell Culture—Breast cancer cell lines (MCF-7, T47-D, BT-20, and
MDA-MB-231) were obtained from the American Type Culture Collec-
tion and routinely grown as monolayer cultures. Cells were maintained
in minimal essential medium (Earle’s salts) supplemented with 20 mM
Hepes, 2 g/liter sodium bicarbonate, 2 mM L-glutamine, 10% fetal calf
serum (FCS), 100 units/ml penicillin-streptomycin, 50 mg/ml gentami-
cin, 1% of non-essential amino acids, and 5 mg/ml insulin.
Detection of Neurotrophin Receptors mRNA Expression —The reverse
transcription reaction mixture contained 2 g of purified total RNA
(extracted from breast cancer cell lines, NT-2 cells, or SY5Y cells), 13
reverse transcription reaction buffer, 10 mM DTT, 400 mM dNTP each,
2.5 M oligo(dT) 18 primer, 40 units of RNasin, and 200 units of Moloney
murine leukemia virus reverse transcriptase were added to 25 ml of
total reaction volume. All the reaction mixtures were incubated at 37 °C
for 1 h and then inactivated at 95 °C for 5 min. Polymerase chain
reaction was performed on cDNAs after RT or corresponding total RNA
samples without the RT step for negative controls. The primers used for
trkA and p75 RT-PCR detection in breast cancer cell lines were as
follows: trkA sense primer, 59 (291)-CATCGTGAAGAGTGTCTCCG-39
(311) and antisense primer, 59 (392)-GAGAGAGACTCCAGAGCGTT-
GAA-39 (370) or p75 sense primer, 59 (442)-CCTACGGCTACTACCAG-
GATGAG-39 (462) and antisense primer, 59 (588)-TGGCCTCGTCG-
GAATACG-39 (571). The primers used for RT-PCR comparative
detection of trks in MCF-7 cells were as follows: trkA sense primer, 59
(118)-AGGCGGTCTGGTGACTTCGTTG-39 (139) and antisense primer,
59 (1162)-GGCAGCCAGCAGGGTGTAGTTC-39 (1141) or trkB sense
primer, 59 (134)-CGAGGTTGGAACCTAACAGCATTG-39 (157) and an-
tisense primer, 59 (1182)-GTCAGTTGGCGTGGTCCAGTCTTC-39
(1159) or trkC sense primer, 59 (219)-CACGGACATCTCAAGGAAGA-
GCA-39 (241) and antisense primer, 59 (1078)-CTGAGAACTTCACCC-
TCCTGGTAG-39 (1056). Each pair of primers was used in RT-PCR
reaction to amplify trks or p75. To PCR tubes were added 5 ml of PCR
buffer (200 mM Tris-HCl, pH 8.4, 500 mM KCl), 10 ml of 15 mM MgCl2,
1 ml of 10 mM dNTP mix, 1 ml of cDNA or total mRNA (for negative
control), 1 ml of 50 mM respective primers, 1 ml of 2.5 units/ml Taq DNA
polymerase, and water to a total volume of 50 ml. The PCR conditions
were as follows: after 95 °C for 3 min for denaturing cDNA, 30 cycles
were run at 94 °C for 1 min, 57 °C for 2 min, and 72 °C for 3 min. The
PCR tubes were incubated for a further 10 min at 72 °C for the exten-
sion of cDNA fragments after the final cycle, and the PCR products were
electrophoresed in an agarose gel.
Cell Growth Assay—Experiments were performed as previously de-
scribed (13). 35-mm diameter dishes were inoculated with 2 3 104
cells/dish in 2 ml of medium containing 10% FCS. After 24 h, cells were
washed twice with serum-free medium. Next day, the medium was
replaced with 2 ml of serum free medium containing 100 ng/ml NGF or
various concentrations of other neurotrophins (BDNF, NT-3, NT-4/5).
To study the effect of pharmacological inhibitors or blocking antibodies,
various concentrations were added simultaneously with NGF (100 ng/
ml). After 2 days of NGF exposure, cells were harvested by trypsiniza-
tion and counted using an hemocytometer.
Determination of the Percentage of Apoptotic Cell Nuclei—Apoptosis
of breast cancer cells was induced by the ceramide analogue C2, which
has been described as a pro-apoptotic agent for human breast cancer
cells (21, 22). Apoptosis was obtained by treatment with 2 mM C2 for
24 h. To evaluate the anti-apoptotic activity of NGF, various concen-
trations of this factor were tested; we found that the maximal effect was
obtained for 100 ng/ml. Consequently, this concentration was used in all
experiments with pharmacological inhibitors or blocking antibody. For
determination of apoptotic cell percentage, cells were fixed with cold
methanol (220 °C) for 10 min and washed twice with phosphate-buff-
ered saline (PBS) before staining with 1 mg/ml Hoechst 33258 for 10 min
at room temperature in the dark. Cells were then washed with PBS and
mounted with coverslips using Glycergel (Dako). The apoptotic cells
exhibiting condensed and fragmented nuclei were counted under an
Olympus-BH2 fluorescence microscope in randomly selected fields. A
minimum of 500–1000 cells was examined for each condition, and
results were expressed as a ratio of the total number of cells counted.
Statistical Analysis and Software—The statistical analysis of the
data gathered from cell and apoptotic nuclei counting was performed
using SPSS version 9.0.1 (SPSS inc., Chicago, IL). Analyses of variance
were followed by the Tukey’s test to determine the significance.
NGF Receptors and PARP Immunoblotting—Subconfluent cell cul-
tures were harvested by scraping in serum-free medium. After centrif-
ugation (1000 3 g, 5 min), the pellet was treated with lysis buffer (0.3%
SDS, 200 mM dithiothreitol) and boiled 5 min. In the case of PARP, the
pellet was lysed with urea-rich buffer (62.5 mM Tris-HCl, pH 6.8, 6 M
urea, 10% glycerol, 2% SDS), sonicated and incubated at 65 °C for 15
min. The lysates were subjected to SDS-PAGE, transferred onto a
nitrocellulose membrane (Immobilon-P, Millipore) by electroblotting
(100 V, 75 min), and probed with anti-trkA, anti-p75NTR or anti-PARP
antibodies at 4 °C overnight. The membranes were then incubated at
room temperature for 3 h with biotin-conjugated anti-rabbit (TrkA) or
anti-mouse (p75NTR and PARP) immunoglobulin G. After 1 h of incu-
bation with extravidin, the reaction was revealed using the chemilumi-
nescence kit ECL (Amersham Pharmacia Biotech) with Kodak X-Omat
AR film.
Detection of p140trkA and MAPK Activation—Proteins were extracted
in lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 0.1% SDS, 1% Nonidet
P-40, 100 mM sodium orthovanadate) prior to immunoprecipitation.
Preclearing was done with protein A-agarose (10 ml/250 ml, 60 min,
4 °C). After centrifugation (10,000 3 g, 2 min), the supernatant was
incubated with monoclonal anti-MAPK (anti-ERK2) antibody (10 ml/250
ml, 60 min, 4 °C). Protein A-agarose (10 ml) was added for 60 min (4 °C)
and then pelleted by centrifugation (10,000 3 g, 2 min). The pellet was
then rinsed three times with lysis buffer and boiled for 5 min in
Laemmli buffer. After SDS-PAGE and electroblotting, nitrocellulose
membranes were blocked with 3% bovine serum albumin. Membranes
were then incubated with PY20 anti-phosphotyrosine antibody over-
night at 4 °C, rinsed, and incubated with a horseradish peroxidase-
conjugated anti-mouse IgG for 3 h at room temperature. Membranes
were rinsed overnight at 4 °C before visualization with ECL.
Cell Fractionation and NF-kB Detection—Cell nuclear extracts were
prepared as described by Herrmann et al. (23). Cells were trypsinized
and then pelleted in minimal essential medium containing 10% FCS.
After washing with ice-cold PBS, cells were repelleted and resuspended
in 400 ml of ice-cold hypotonic buffer (10 mM Hepes, pH 7.8, 10 mM KCl,
2 mM MgCl2, 0.1 mM EDTA, 10 mg/ml aprotinin, 0.5 mg/ml leupeptin, 3
mM phenylmethylsulfonyl fluoride, and 3 mM DTT). After 10 min on ice,
25 ml of 10% Nonidet P-40 was added and crude nuclei were collected by
centrifugation for 5 min. The nuclear pellet was resuspended in high
salt buffer (50 mM Hepes, pH 7.4, 50 mM KCl, 300 mM NaCl, 0.1 mM
EDTA, 10% (v/v) glycerol, 3 mM DTT, and 3 mM phenylmethylsulfonyl
fluoride). After 30 min on ice with frequent agitation, the insoluble
nuclear material was pelleted in a microcentrifuge for 10 min. Crude
nuclear protein was collected from the supernatant and snap-frozen in
a dry ice/ethanol bath. After thawing and boiling for 5 min in Laemmli
buffer, the nuclear extracts were subjected to SDS-PAGE and probed
with an anti-NF-kB p65 antibody. A control was established with anti-
lamin B antibody.
Transfection of Ikb, c-rel, and rel-A—Cotransfection experiments
were carried out using Lipofectin reagent, as described by the manu-
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facturer. Briefly, MCF-7 cells were incubated for 5 h in 1 ml of Opti-
MEM transfection medium containing 8 ml of Lipofectin reagent, 0.8 mg
of green fluorescence protein (GFP)-carrying vector and 0.2 mg of empty
vector PCDNA3 or 0.2 mg of IkBm. In the case of c-rel or rel-A, cells were
cotransfected with 0.8 mg of GFP-carrying GFP and 0.6 mg of PSVK3
(empty plasmid), c-rel, or rel-A. Cells were then grown for 24 h with 10%
FCS minimal essential medium and rinsed for 2 h in serum-free me-
dium before incubation in serum-free medium in the presence or ab-
sence of 100 ng/ml NGF and/or 2 mM C2 for another 24 h. Cells were
then fixed with paraformaldehyde 4% (4 °C) for 30 min, and the per-
centage of apoptotic cell nuclei in GFP-stained cells was determined as
described above.
RESULTS
NGF Mitogenic and Anti-apoptotic Activity for Breast Cancer
Cells—The effects of 100 ng/ml NGF on cell proliferation and
C2-induced apoptosis were evaluated by cell counting and
Hoechst staining, respectively. The results show that NGF
induces an increase in cell number for all breast cancer cell
lines tested (Fig. 1A). We have previously demonstrated that
NGF has a direct mitogenic effect on breast cancer cells by
recruiting cells in G0 phase and by shortening the G1 length
(Descamps et al., 1998). In addition, NGF rescued breast cancer
cells undergoing C2-induced apoptosis; the maximum survival
was observed at 200 ng/ml (Fig. 1B). The morphology of cells
undergoing this NGF-induced anti-apoptotic rescue was quite
distinct (Fig. 2A). The induction of apoptosis by C2 was found to
involve cleavage of poly(A)DP-ribose polymerase (PARP); this
cleavage was reversed by NGF (Fig. 2B).
TrkA and p75NTR Expression—RT-PCR was used to show the
expression of mRNA for both high and low affinity NGF recep-
tors in MCF-7, T47-D, BT-20, and MDA-MB-231 cells (Fig. 3A);
the 102-bp band for the TrkA transcript and a 147-bp band for
the p75NTR transcript were readily detectable on 1% agarose
gels. Moreover, Western blotting demonstrated that both
p140trkA and p75NTR were present in all the breast cancer cell
lines (Fig. 3B). Real-time quantitative RT-PCR indicated that
there was no significant change in the levels of TrkA and
p75NTR mRNAs in the presence of FCS, NGF, or C2 (data not
shown) and that the levels of mRNA for TrkA and p75NTR in
breast cancer cells was between 5 and 10 times lower than the
level observed in SY5Y neuroblastoma cells (data not shown).
This indicates that NGF receptor expression in breast cancer
cells is relatively limited. It should be noticed that, although
mRNA levels of NGF receptors differ between breast cancer
cells and SY5Y, the protein levels apparently do not. However,
FIG. 1. Effect of NGF on the growth and survival of breast
cancer cells. A, breast cancer cells were serum-deprived in minimum
essential medium, and after 24 h the NGF (100 ng/ml) was added. After
48 h, cells were harvested and counted. B, cells were serum-deprived in
minimum essential medium and treated with 2 mM C2 with or without
100 ng/ml NGF. After 24 h, cells were fixed and the proportion of
apoptotic nuclei were determined after Hoechst staining under an
Olympus-BH2 fluorescence microscope. For measurement of both cell
number and apoptosis, results are expressed as the means 6 S.D. of five
separate experiments. Significance was determined using the Tukey’s
test (*, p , 0.01).
FIG. 2. Anti-apoptotic effect of NGF. A, Hoechst staining of apop-
totic cell nuclei in control, C2 and C21NGF-treated MCF-7 cells. Cells
were serum-deprived in minimum essential medium and treated with
C2. NGF was added at 100 ng/ml. After 24 h, cells were fixed and
apoptotic nuclei were observed after Hoechst staining. B, immunoblot
detection of PARP cleavage. C2-induced PARP cleavage was reversed
by p75NTR activation mediated by NGF. MCF-7 cells were serum-de-
prived in minimum essential medium for 24 h and were then treated
with 100 ng/ml NGF in the presence or absence of 2 mM C2, 10 nM
K-252a, 10 mM PD98059, or 10 mg/ml anti-p75NTR-blocking antibody
(Euromedex) for another 24-h period. Proteins were detected after SDS-
PAGE of cell preparations from MCF-7 breast cancer cells, electro-
blotting onto nitrocellulose, and immunodetection with anti-PARP
antibodies.
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it has been shown before that the level of a given cellular
protein cannot be simply deduced from mRNA transcript level
(24). One could hypothesize that the stability of mRNA and/or
protein for NGF receptors, differs between breast cancer cells
and neuroblastoma cells, leading to the observed disproportion-
ality between mRNA and protein levels.
Involvement of p140trkA and p75NTR in Mitogenic and Sur-
vival Activities of NGF—We used a combination of specific
antibodies and pharmacological inhibitors to study the puta-
tive functions of p140trkA and p75NTR in the stimulation of
proliferation and cell survival induced by NGF. The Trk tyro-
sine kinase inhibitor K-252a, and the MEK inhibitor PD98059,
both strongly inhibited the growth-stimulatory effect of NGF
on MCF-7 cells, but had no effect on its anti-apoptotic effects
(Fig. 4). Conversely, neither the anti-p75NTR blocking antibody
nor the NF-kB inhibitor SN50 affected NGF-stimulated prolif-
eration, although both strongly reduced the anti-apoptotic ef-
fects (Fig. 4). The tyrosine kinase activity of p140trkA was
inhibited by K-252a but not by the anti-p75NTR or PD98059
(Fig. 5). On the other hand, the activity of the MAPKs was
inhibited by K-252a and PD98059 but not by the anti-p75NTR
(Fig. 5). It should be noted that the SN50 peptidic inhibitor of
NF-kB, similarly to the anti-p75NTR, inhibited the anti-apo-
ptotic effect of NGF but neither its proliferative effect nor its
activation of p140trkA and MAPKs. The effect of other neuro-
trophins on MCF-7 cell growth and survival was also evaluated
(Fig. 6A). In contrast to NGF, no proliferative effect was pro-
vided by BDNF, NT-3, or NT-4/5. However, all neurotrophins
tested exhibited a rescue effect on C2-treated cells that was not
altered in the presence of the trk inhibitor K-252a (Fig. 6B).
These data suggest that trk receptors are not involved in NGF
survival activity. Moreover, the participation of trkB and trkC
in these events can be ruled out, because they are not expressed
in these breast cancer cells (Fig. 6C).
NF-kB Involvement in the Anti-apoptotic Effect of NGF—The
inhibitory effect of SN50 on the NGF anti-apoptotic activity
indicated the potential involvement of NF-kB in the signaling
leading to the protective activity of this growth factor. To fur-
ther investigate this phenomenon, we studied the effect of NGF
on the nuclear translocation of NF-kB, as well as the conse-
quence of transfection by IkBm (an inhibitor of NF-kB) or by
c-rel and rel-A (constitutively active subunits of NF-kB) on the
NGF-mediated anti-apoptotic activity in MCF-7 cells. Western
blotting revealed no change in the nuclear levels of NF-kB (p65)
during apoptosis induced by C2 (Fig. 7). In contrast, the addi-
tion of NGF on C2-treated cells induced a translocation of
NF-kB from cytoplasm to nucleus. Computerized quantifica-
tion revealed a doubling p65 band intensity normalized to the
total intensity of the lane (data not shown). Moreover, this
NF-kB nuclear translocation was inhibited by the presence of
p75NTR-blocking antibody or SN50, but was not affected by
K-252a and PD98059. Interestingly, in the absence of C2-in-
duced apoptosis NGF was not able to induce the nuclear trans-
location of NF-kB, confirming previous observations that
p75NTR-mediated NF-kB activation requires cell stress (25).
Transfection of MCF-7 cells with IkBm, an inhibitor of NF-kB,
reversed the anti-apoptotic effect of NGF (Fig. 8A). As a control,
we transfected MCF-7 cells with an empty vector; no effect was
observed. In addition, transfection with activators of the NF-kB
pathway, c-rel or rel-A (Fig. 8B), resulted in an inhibition of
C2-induced apoptosis of MCF-7 cells, even in absence of NGF,
FIG. 3. TrkA and p75NTR expression in breast cancer cells. A,
agarose gel electrophoresis of RT-PCR products evidenced a 102-bp
band and a 147-bp band, which are characteristic of TrkA and p75NTR,
respectively. Both NGF receptors were found in all cell types tested. B,
p140trkA and p75NTR were immunodetected after SDS-PAGE of breast
cancer cell lines. The neuroblastoma cells SY5Y were used as positive
control for the expression of NGF receptors.
FIG. 4. Pharmacological modulation of the proliferative and
anti-apoptotic effect of NGF. MCF-7 cells were starved in minimum
essential medium, and after 24 h, 100 ng/ml NGF was added with or
without inhibitors or antibody. A, after 48 h, cells were harvested and
counted. B, after 24 h, cells were fixed and the proportion of apoptotic
nuclei determined after Hoechst staining. The following concentrations
were used: 2 mM C2, 10 nM K-252a, 10 mg/ml anti-p75NTR-blocking
antibody (Euromedex), 10 mM PD98059, 18 mM SN50. For A and B,
results are expressed as the means 1 S.D. of five separate experiments.
Significance was determined using the Tukey’s test (*, p , 0.01).
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confirming the involvement of NF-kB family members in hu-
man breast cancer cell survival.
DISCUSSION
This study shows that, in addition to its mitogenic activity,
NGF is anti-apoptotic for breast cancer cells, and that these
two biological effects are differentially mediated by the
p140trkA and p75NTR receptors, respectively. The growth of
breast cancer results from a balance between cell proliferation
and apoptosis, both of which can be modulated by various
regulatory peptides. For example, epidermal growth factor,
fibroblast growth factors, and insulin-like growth factor-1 can
all stimulate the proliferation and survival of breast cancer
cells (26). On the other hand, agents such as transforming
growth factor-b or tumor necrosis factor-a can inhibit growth
and induce apoptosis in these cells (27). Recently we have
shown that NGF, which was primarily described for its neuro-
trophic properties, is a strong mitogen for cancerous but not for
normal human breast epithelial cells, suggesting a crucial func-
tion for this factor in the initiation and progression of human
breast tumors (13). In the present study, we have shown that
the breast cancer cells express transcripts for both TrkA and
p75NTR receptors. In contrast, no expression of TrkB and TrkC
was found in any of the breast cancer cells tested, in accordance
with the fact that BDNF, NT-3, or NT-4/5 have no mitogenic
effect for these cells. The presence of NGF receptors has been
detected previously in breast cancer cells (28), and low levels of
NGF receptor expression have recently been reported in other
breast cancer cell lines (29), leading to the hypothesis of a
recruitment and cooperation between p140trkA and p185Her-2
for the induction of mitogenesis by NGF. Our results indicate a
stimulation of p140trkA tyrosine kinase activity and of the
MAPK cascade by NGF, and the use of the pharmacological
inhibitors K-252a and PD98059 demonstrate the requirement
for these signals in NGF-induced MCF-7 cell proliferation. The
induction of MAPK activity required p140trkA activation, but
p75NTR did not appear to be involved, because p75NTR-blocking
antibodies did not have any effect on NGF-induced MAPK
FIG. 5. p140trkA and MAPK activation. MCF-7 cells were treated
with 100 ng/ml NGF in the presence or absence of 10 nM K-252a, 10
mg/ml anti-p75NTR-blocking antibody, or 10 mM PD98059. p140trkA (A)
and MAPK activation (B) were determined after immunoprecipitation
using polyclonal anti-TrkA and monoclonal anti-ERK2 antibodies, re-
spectively. After SDS-PAGE and electroblotting, nitrocellulose mem-
branes were counterprobed with the PY20 anti-phosphotyrosine anti-
body. For detection of TrkA (A) and MAPK (B) activation, the lower
panel shows reprobing of the blots with the immunoprecipitating
antibody.
FIG. 6. Effect of different neurotrophins on MCF-7 cells
growth and survival. MCF-7 cells were serum-deprived in minimum
essential medium, and after 24 h the neurotrophins (100 ng/ml NGF, 50
ng/ml BDNF, 50 ng/ml NT-3, 100 ng/ml NT-4/5) were added. A, after
48 h, cells were harvested and counted. In contrast with NGF, neither
BDNF, NT-3, nor NT-4/5 displayed significant bioactivity (for concen-
trations up to 400 ng/ml). B, MCF-7 cells were serum-deprived in
minimum essential medium and treated with 2 mM C2, with or without
neurotrophins (100 ng/ml NGF, 50 ng/ml BDNF, 50 ng/ml NT-3, 100
ng/ml NT-4/5). After 24 h, cells were fixed and apoptotic nuclei percent-
age was determined after Hoechst staining under an Olympus-BH2
fluorescence microscope. For measurement of both cell number and
apoptosis, results are expressed as the means 6 S.D. of five separate
experiments. Significance was determined using the Tukey’s test (*,
p , 0.01). C, TrkB and TrkC mRNA expression in MCF-7 cells. Agarose
gel electrophoresis of RT-PCR products reveals TrkA expression, but no
TrkB or TrkC expression in MCF-7 breast cancer cells. Human NT2
cells were used as positive control for the expression of TrkB and TrkC.
Lane 1, NT2-negative control without RT step; lane 2, NT2-positive
control; lane 3, MCF-7 cells-negative control without RT step; lane 4,
MCF-7 cells.
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activation and cell proliferation. In contrast, p75NTR-blocking
antibodies exhibited an inhibition of NGF-induced survival,
attesting to the functionality of these blocking antibodies.
Thus, the mitogenic activity of NGF requires the p140trkA and
MAPK cascade independently of the p75NTR receptor. This
signaling pathway for the NGF-proliferative effect appears to
be similar to that which is described for the neurotrophic ac-
tivity of this factor. For example, in PC-12 pheochromocytoma
cells, disruption of p75NTR does not result in an inhibition of
the NGF differentiative activity, which is mediated by the
p140trkA/MAPK pathway (30). Interestingly, it has also been
shown in PC-12 cells that NGF induces survival and differen-
tiation through two distinct signaling pathways, because the
activation of the MAPK cascade is required for the differentia-
tive but not the protective activity of NGF (31). These data
emphasize the similarities between the mitogenic and neuro-
trophic signaling pathways of NGF.
The function of NGF as a survival factor has been exten-
sively described for neurons in both in vitro and in vivo (32).
However, the intracellular signaling involved in the anti-apo-
ptotic activity of NGF in neurons remains controversial. The
p140trkA/MAPK cascade is generally described as protective for
neuronal cell death, although there has been a recent report of
a novel apoptotic pathway mediated by p140trkA/MAPK in
medulloblastoma cells (33). Unlike the p140trkA receptors, the
definition of the precise physiological role of p75NTR has proven
difficult (4). The p75NTR receptor belongs to the TNF-receptor
family, including among others, types I and II of the TNF
receptor, the Fas antigen, and CD40 (34). The common cellular
responses to activation of this family of receptors are the acti-
vation of gene transcription via nuclear factor-kB (NF-kB) and
the regulation of cell survival/apoptosis. In some cases apopto-
sis was shown to develop following NGF binding to p75NTR,
although in other cases it appeared to occur in the absence of
ligand (spontaneous apoptosis) and was reversed by NGF (35).
The C2 reagent used here is known to induce apoptosis in
breast cancer cells such as MCF-7 (21, 22). Morphological anal-
ysis after Hoechst staining and the inhibition of PARP cleavage
demonstrated that NGF rescues breast cancer cells from C2-
induced cell death. Interestingly, K-252a and PD98059 did not
affect the anti-apoptotic activity of NGF, indicating that
p140trkA tyrosine kinase and MAPK activities are not neces-
sary for the protective effect. Previous reports have noted that
NGF is able to elicit its biological effects through p75NTR re-
ceptors and independently of p140trkA in neurons (36, 37) and
Schwann cells (38). In our experiments, a specific role for
p75NTR in the cell survival effect was first suggested by the fact
that other neurotrophins (interacting with p75NTR and not
with p140trkA) are also able to protect cells from death while
having no impact on cell proliferation. The crucial role of
p75NTR was further demonstrated by the use of p75NTR-block-
ing antibodies, which completely reversed the protective effect
of NGF from C2-induced apoptosis. Moreover, BDNF, NT-3,
and NT-4/5, all of which can bind P75NTR, can also stimulate
breast cancer cell survival. Because TrkB and TrkC are not
expressed in breast cancer cells, these data emphasize the role
played by p75NTR in the anti-apoptotic effect of NGF. Activa-
tion of p75NTR specifically induces NF-kB independent of
p140trkA in several cell types, including Schwann cells (38). To
explore the involvement of NF-kB in the NGF survival effect,
we first tested SN50, which inhibits the nuclear translocation
of this transcription factor (39). We found that it blocked the
anti-apoptotic effect of NGF without affecting the p140trkA/
MAPK cascade or cellular proliferation. The involvement of
FIG. 7. Activation of NF-kB during
NGF anti-apoptotic effect. MCF-7 cells
were treated with 100 ng/ml NGF in the
presence or absence of 10 nM K-252a, 10
mM PD98059, or 10 mg/ml anti-p75NTR
blocking antibody (Euromedex). Proteins
were detected after SDS-PAGE of nuclear
extract preparations and immunoblotting
with rabbit anti-NF-kB p65. The lower
panel shows immunoblotting with anti-
lamin B.
FIG. 8. Modulation of NGF anti-apoptotic effect by IkBm, c-rel,
and rel-A transfection. MCF-7 cells were co-transfected with
EGFPC1 and either IkBm (A) or c-rel or rel-A (B) using the Lipofectin
reagent. Controls were performed with both PCDNA3 and EGFPC1 (for
IkBm experiments) and both PSVK3 and EGFPC1 (for c-rel and rel-A
experiments). After 24 h, cells were serum-deprived in minimum essen-
tial medium and either C2 or neurotrophins added for another 24-h
period. Cells were then fixed and the percentage of apoptotic nuclei in
transfected cells (with the expression of GFP as a transfection control)
determined after Hoechst staining. Results are expressed as the
means 6 S.D. of six separate experiments. Significance was determined
using the Tukey’s test (*, p , 0.01).
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NF-kB was further demonstrated by transfection with a mu-
tated form of IkBa, which blocked NF-kB translocation to the
nucleus. MCF-7 cells transfected by mutated IkBa were not
rescued from C2-induced apoptosis by NGF, confirming the
involvement of NF-kB in the anti-apoptotic activity mediated
by p75NTR. Similar observations have been made in PC12 cells
in which the blocking of p75NTR-mediated activation of NF-kB
resulted in an enhancement of apoptosis (40). In addition,
transfections by c-rel or rel-A, which are constitutively acti-
vated forms of NF-kB, had a protective effect on MCF-7 cells
treated by C2 in absence of NGF stimulation. c-rel and rel-A
belong to the NF-kB family of transcription factors. The pro-
tection from apoptosis observed after transfection with this
factor emphasizes the role played by NF-kB molecules in the
control of breast cancer cell survival.
In conclusion, our results demonstrate that NGF is an anti-
apoptotic factor for human breast cancer cells and that the
signaling pathway leading to this survival activity is distinct
from the signaling pathway, which leads to mitogenic stimula-
tion. Although p140trkA and the MAPKs mediate the mitogenic
activity of NGF, its anti-apoptotic activity required p75NTR and
NF-kB alone. NGF is present in the mammary gland (41, 42) as
well as its transcripts,2 and our present finding therefore em-
phasizes that NGF is a crucial regulator of mammary tumor
growth. The inhibition of breast cancer progression through the
targeting p140trkA and p75NTR should be considered as a po-
tential perspective for the treatment of this pathology.
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